KONINKLIJKE PHILIPS NV annual report, Q4 FY2020

Full document

Business context and reporting period

Koninklijke Philips N.V. filed this Form 20-F on February 23, 2021, covering the fiscal year ended December 31, 2020. It is an annual report, not a standalone Q4 filing; the supplied text does not provide clear Q4-only financial results. The audited consolidated statements are prepared under IFRS as endorsed by the EU and also comply with IFRS as issued by the IASB. Philips operates in health technology across Diagnosis & Treatment, Connected Care, Personal Health and Other.

Financial performance and position

  • Sales: EUR 19.535 billion, up 0.3% nominally from 2019. Comparable sales growth was 2.5% in the financial tables; the CEO message describes growth as 3%, apparently rounded. Foreign exchange was a drag.
  • Segment sales: Diagnosis & Treatment EUR 8.175 billion, down 2.3% comparable; Connected Care EUR 5.564 billion, up 22.0%; Personal Health EUR 5.407 billion, down 4.2%.
  • Profit and margins: Net income was EUR 1.195 billion, up EUR 22 million. Income from operations was EUR 1.542 billion, or 7.9% of sales, down from 8.4%. Gross margin was 45.0%, down from 45.6%. Adjusted EBITA, a non-IFRS measure, was EUR 2.570 billion, or 13.2% of sales, essentially unchanged as a percentage of sales.
  • Segment Adjusted EBITA margins: Diagnosis & Treatment 10.0% (12.7% in 2019); Connected Care 21.5% (13.2%); Personal Health 13.0% (16.1%).
  • Cash flow: Operating cash flow was EUR 2.777 billion, up from EUR 2.031 billion, mainly reflecting improved working capital and receivables management. Free cash flow, a non-IFRS measure, was EUR 1.852 billion, versus EUR 1.053 billion.
  • Debt and liquidity: Year-end gross debt was EUR 6.934 billion, cash and cash equivalents EUR 3.226 billion, and net debt EUR 3.708 billion. Available liquidity, including cash and a EUR 1 billion committed revolving facility, was EUR 4.226 billion; there were no borrowings under that facility. Debt increased from EUR 5.447 billion in 2019. Long-term debt was 82.3% of total debt, with a 6.3-year average remaining term.
  • Other metrics: R&D expense was EUR 1.915 billion, or 9.8% of sales. Year-end shareholders’ equity was EUR 11.870 billion, down EUR 727 million, mainly reflecting EUR 1.037 billion of currency translation losses and share repurchases. Diluted earnings per share from continuing operations were EUR 1.31.

Material changes versus 2019

  • COVID-19 produced divergent segment trends: strong demand drove Connected Care growth, while postponed installations and elective procedures weighed on Diagnosis & Treatment and lockdown-related consumer weakness hurt Personal Health.
  • Connected Care Adjusted EBITA margin expanded sharply, while margins declined in Diagnosis & Treatment and Personal Health. Group Adjusted EBITA margin remained 13.2%.
  • Operating cash flow and free cash flow improved substantially. Cash increased to EUR 3.226 billion, alongside higher gross debt.
  • Philips recorded EUR 144 million of goodwill impairment, primarily related to Population Health Management and Aging and Caregiving. The filing also reports a EUR 92 million technology-asset impairment in Image-Guided Therapy.
  • Philips completed three acquisitions, including Intact Vascular, and made no divestments in 2020. BioTelemetry was acquired on February 9, 2021; the Capsule Technologies acquisition was announced in January 2021 and remained subject to closing conditions.

Outlook, commentary, risks and unusual items

  • 2021 outlook: Philips expected low-single-digit comparable sales growth and 60–80 basis points of Adjusted EBITA margin improvement, with solid growth in Diagnosis & Treatment and Personal Health partly offset by lower Connected Care sales. Management cited continuing uncertainty from COVID-19.
  • 2021–2025 targets: Average annual Group comparable sales growth of 5–6%, average annual Adjusted EBITA margin improvement of 60–80 basis points from 2021, free cash flow above EUR 2 billion by 2025, and organic ROIC in the mid-to-high teens by 2025. These targets exclude Domestic Appliances.
  • Portfolio changes and dividend: Philips was separating Domestic Appliances into a distinct legal structure, expected to be completed in Q3 2021; the business generated EUR 2.2 billion of 2020 sales and was not classified as held for sale at year-end. Management proposed a EUR 0.85-per-share dividend, payable in cash or shares at shareholder option, subject to approval.
  • Significant charges and estimates: Restructuring, acquisition-related and other charges totaled EUR 504 million. Other notable items included EUR 38 million of legal provisions and EUR 42 million of Domestic Appliances separation costs. Goodwill and other asset valuations, tax assets, sales-related accruals and legal contingencies involve management judgments.
  • Risks and contingencies: Principal risks include pandemic-related demand and supply disruption, cybersecurity and IT failures, product quality and regulatory compliance, supplier concentration and shortages, foreign exchange and counterparty exposure, tax and pension risks, and execution of acquisitions and the Domestic Appliances separation. The US defibrillator consent decree remains in effect, although FDA requirements to resume US manufacture and distribution were met in April 2020. Regulatory investigations and litigation remain, including Brazilian tender matters and CRT-related claims; some potential losses could not be reliably estimated. The filing reports EUR 72 million of legal provisions and EUR 16 million of off-balance-sheet business guarantees at year-end.
  • Controls and audit: Management and the auditor concluded internal control over financial reporting was effective at December 31, 2020. The auditor issued unqualified opinions on both the consolidated financial statements and internal control.

Important facts for investors to verify

  • How COVID-19 demand normalizes across Connected Care and the other businesses, and whether the 2021 sales and margin outlook is achieved.
  • Whether Connected Care’s exceptional 2020 growth and margin expansion are sustainable, and whether weaker margins in the other segments recover.
  • Progress, costs and eventual ownership outcome for Domestic Appliances, and the effect of excluding it from the 2021–2025 targets.
  • Integration and financial effects of BioTelemetry and Capsule Technologies, including Capsule’s closing and purchase accounting.
  • Assumptions behind the EUR 144 million goodwill impairment, remaining goodwill valuations, and other material impairment estimates.
  • Developments in legal proceedings, investigations and the consent decree, including any future cash costs or operational restrictions.
  • Debt, liquidity and share-buyback settlement obligations, including EUR 11.650 billion of disclosed undiscounted contractual cash obligations.
  • Approval and settlement of the proposed EUR 0.85 dividend and the reliability of non-IFRS measures, which Philips cautions may not be comparable across issuers.